ASH: Geron's 'drug works' in myelofibrosis, despite 'possibly related' deaths
This article was originally published in Scrip
Executive Summary
Menlo Park, California-based Geron has revealed preliminary data from the ongoing Mayo Clinic investigator-sponsored trial (IST) for its telomerase inhibitor imetelstat, which is being tested as a treatment for myelofibrosis. Even though two patients out of 22 in the initial cohort have died, one of the investigators said that the drug "clearly shows antimyeloproliferative activity." Geron's CEO told investors that dose reductions during Mayo's trial meant that the myelosuppression side effect seen by some patients was "clearly manageable."
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.